Semaglutide's structure is a modified backbone with a C18 diacid attached through a spacer. The acylation is the reason for the long half-life and it is also the reason a plain sequence comparison against native GLP-1 is misleading about how the molecule behaves.
The claim is narrower than it sounds, and deliberately so.
Good question, well framed, and I would like to see it answered properly.
Worth separating two things this subcategory keeps merging: what the molecule does, which is reasonably well characterised, and what a particular vial contains, which is a documentation question and has nothing to do with pharmacology.
The arithmetic in post #31 is right; the assumption feeding it is the part to check.
The most useful thing anyone has posted about Molecular mass of semaglutide in this category was a table of what had been measured and by whom. That is what I would want again.
Speaking only to Molecular mass of semaglutide as I have actually seen it, rather than as it is usually described: the effect is real, it is smaller than the thread suggests, and the variance between people is larger than the effect.
Practical note on Molecular mass of semaglutide: write down what you expect before you look. The number of times I have found what I went looking for is higher than chance would allow.
Injection site does not appear to matter much for semaglutide exposure. The published comparisons of abdomen, thigh and upper arm found differences small enough to be clinically unimportant, which is not true of every injectable.
On alcohol: the labelling does not contraindicate it, but it raises gastric irritation risk and semaglutide already does that. There is no published interaction study and the conservative position is to limit it if you are titrating or if gastrointestinal symptoms are troublesome.
I would put this at better than even and not much better.
Read the full topic (103 posts)
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Revisiting: Is there a ceiling dose beyond which semaglutide stops adding benefit?
Revisiting: Is there a ceiling dose beyond which semaglutide stops adding benefit? — that is the question, and I have not found it answered plainly anywhere I have looked. Putting the numbers in the first…
|
+5 | 9 | 30k | 8d |
|
Revisiting: What SELECT changed about how semaglutide is discussed, and what it did not
Revisiting: What SELECT changed about how semaglutide is discussed, and what it did not Writing it up because I had to work it out twice and would rather nobody else did. I was wrong about SELECT in a thread…
|
2 | 1.9k | 5mo | |
|
Semaglutide half-life: where the 165 to 184 hour figure comes from
Semaglutide half-life: where the 165 to 184 hour figure comes from — setting out what I have, and where I think it stops being reliable. Putting the numbers in the first post, because a question about a…
|
+128 | 145 | 3k | 4mo |
|
Comparing the STEP programme populations: who was actually enrolled — the long version
On the subject in the title: Comparing the STEP programme populations: who was actually enrolled — the long version Working notes rather than a conclusion. A narrow question about Comparing the STEP programme…
|
4 | 7.7k | 11mo | |
|
Semaglutide in people without diabetes: what the evidence base looks like
Semaglutide in people without diabetes: what the evidence base looks like Writing it up because I had to work it out twice and would rather nobody else did. What changes if the standard account of semaglutide…
|
+2 | 6 | 18k | 17mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Why fasting instructions for oral semaglutide are not optional advice — does this still hold?
Asking directly, because I could not find a straight answer: Why fasting instructions for oral semaglutide are not optional advice — does this still hold? A methods question rather than a substantive one,…
|
+98 | 106 | 3.1k | 10mo |
|
About the N-of-1 designs category
Designing a personal experiment that could actually change your mind, including washouts and blinding. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…
|
4 | 22k | 14h | |
|
Revisiting: Semaglutide formulation: what is in the licensed product besides the peptide
Posting this under the heading it deserves: Revisiting: Semaglutide formulation: what is in the licensed product besides the peptide Everything below is what sits behind that. I have spent a fortnight trying…
|
+72 | 77 | 7.2k | 19mo |
|
Criticising the method without criticising the authors — one year on
On the subject in the title: Criticising the method without criticising the authors — one year on Working notes rather than a conclusion. A methods question rather than a substantive one, about Criticising…
|
+16 | 20 | 61k | 11mo |
|
PCOS and metabolic overlap: what is and is not studied
On the subject in the title: PCOS and metabolic overlap: what is and is not studied Working notes rather than a conclusion. PCOS and metabolic overlap, from the point of view of someone who has read the…
|
3 | 6.6k | 1d |